Alterity Therapeutics (ATHE) Competitors $5.44 +0.13 (+2.45%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE vs. DMAC, CRDF, RAPT, LYEL, ACRS, SLS, CLLS, VYGR, DERM, and CTORShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include DiaMedica Therapeutics (DMAC), Cardiff Oncology (CRDF), Rapt Therapeutics (RAPT), Lyell Immunopharma (LYEL), Aclaris Therapeutics (ACRS), SELLAS Life Sciences Group (SLS), Cellectis (CLLS), Voyager Therapeutics (VYGR), Journey Medical (DERM), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. Its Competitors DiaMedica Therapeutics Cardiff Oncology Rapt Therapeutics Lyell Immunopharma Aclaris Therapeutics SELLAS Life Sciences Group Cellectis Voyager Therapeutics Journey Medical Citius Oncology Alterity Therapeutics (NASDAQ:ATHE) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Do institutionals & insiders hold more shares of ATHE or DMAC? 2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, ATHE or DMAC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/ADiaMedica TherapeuticsN/AN/A-$24.44M-$0.64-7.03 Is ATHE or DMAC more profitable? Alterity Therapeutics' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A DiaMedica Therapeutics N/A -61.35%-55.53% Do analysts prefer ATHE or DMAC? Alterity Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 120.59%. DiaMedica Therapeutics has a consensus price target of $10.75, suggesting a potential upside of 139.05%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, ATHE or DMAC? Alterity Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Does the media prefer ATHE or DMAC? In the previous week, DiaMedica Therapeutics had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 1 mentions for DiaMedica Therapeutics and 0 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.00 equaled DiaMedica Therapeutics'average media sentiment score. Company Overall Sentiment Alterity Therapeutics Neutral DiaMedica Therapeutics Neutral SummaryDiaMedica Therapeutics beats Alterity Therapeutics on 6 of the 10 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.21M$2.98B$5.46B$9.67BDividend YieldN/A2.46%3.99%4.14%P/E RatioN/A17.9229.9924.97Price / SalesN/A174.22375.5577.11Price / CashN/A41.8335.9458.58Price / Book5.237.308.165.68Net Income-$12.54M-$54.43M$3.25B$265.38M7 Day Performance8.58%0.07%1.11%2.52%1 Month Performance32.36%5.24%2.80%1.86%1 Year Performance335.20%10.72%28.49%24.21% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics1.7382 of 5 stars$5.44+2.4%$12.00+120.6%+308.5%$48.21MN/A0.0010Gap DownDMACDiaMedica Therapeutics1.4468 of 5 stars$4.36+5.8%$10.75+146.6%+48.3%$176.68MN/A-6.8120CRDFCardiff Oncology1.9648 of 5 stars$2.51-4.9%$11.70+366.1%+12.6%$175.63M$680K-2.8920News CoverageUpcoming EarningsAnalyst ForecastAnalyst RevisionRAPTRapt Therapeutics4.5379 of 5 stars$10.76+2.6%$20.57+91.2%-46.8%$173.46M$1.53M-0.5680Earnings ReportAnalyst ForecastGap UpLYELLyell Immunopharma3.3319 of 5 stars$11.37+3.2%$15.00+31.9%-59.9%$170.34M$60K-0.45270ACRSAclaris Therapeutics2.1778 of 5 stars$1.56+2.0%$8.71+458.6%+31.9%$165.67M$18.72M-1.12100News CoverageEarnings ReportSLSSELLAS Life Sciences Group1.7412 of 5 stars$1.59-4.2%$7.00+340.3%+36.8%$165.63M$1M-4.1810Upcoming EarningsCLLSCellectis2.2311 of 5 stars$3.02+2.4%$4.00+32.5%+31.0%$163.97M$49.22M-3.51290Earnings ReportGap UpVYGRVoyager Therapeutics3.92 of 5 stars$3.21+8.4%$13.39+317.1%-54.3%$163.80M$80M-2.20100Earnings ReportAnalyst ForecastHigh Trading VolumeDERMJourney Medical1.8925 of 5 stars$7.14+2.1%$9.50+33.1%+48.4%$162.84M$56.13M-18.3190News CoverageUpcoming EarningsCTORCitius Oncology1.0669 of 5 stars$2.06flat$3.00+45.6%N/A$161.44MN/A0.00N/A Related Companies and Tools Related Companies DMAC Competitors CRDF Competitors RAPT Competitors LYEL Competitors ACRS Competitors SLS Competitors CLLS Competitors VYGR Competitors DERM Competitors CTOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHE) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHE Stock Alerts